 RedHill Biopharmas Opaganib Demonstrates Strong Inhibition of COVID-19 Delta Variant Opaganib demonstrated strong inhibition of COVID-19 Delta variant in a human bronchial epithelial cells model, adding to prior data demonstrating potent inhibition of all COVID-19 variants tested to date -- Opaganibs unique, host-targeted, dual antiviral and anti-inflammatory approach to combatting COVID-19 is expected to maintain effect against other emerging variants -- The global 475-patient Phase 23 study with opaganib oral pill in hospitalized COVID-19 patients has completed treatment and follow up phase, with top-line results upcoming TEL AVIV, ISRAEL and RALEIGH, NC ACCESSWIRE August 26, 2021 RedHill Biopharma Ltd. NASDAQ:RDHL RedHill or the Company, a specialty biopharmaceutical company, today announced preliminary results of a new preclinical study showing strong inhibition by opaganib ABC2946401 of Delta variant replication while maintaining cell viability at relevant concentrations. 